Publicaciones en colaboración con investigadores/as de Clínica Universitaria de Navarra (222)

2024

  1. Circulating miR-122-5p, miR-151a-3p, miR-126-5p and miR-21-5p as potential predictive biomarkers for Metabolic Dysfunction-Associated Steatotic Liver Disease assessment

    Journal of Physiology and Biochemistry

  2. Dietary carbohydrate quality index and incidence of obesity-related cancers in the “Seguimiento Universidad De Navarra” (SUN) prospective cohort

    European Journal of Nutrition, Vol. 63, Núm. 7, pp. 2449-2458

  3. Differential mitochondrial adaptation and FNDC5 production in brown and white adipose tissue in response to cold and obesity

    Obesity

  4. Estudio de estabilidad fisicoquímica y microbiológica de dos nuevos colirios de metilprednisolona sin conservantes

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 48, Núm. 4, pp. 145-152

  5. FNDC4 reduces hepatocyte inflammatory cell death via AMPKα in metabolic dysfunction-associated steatotic liver disease

    Clinical Nutrition, Vol. 43, Núm. 9, pp. 2221-2233

  6. Increased expression of IL-1β in adipose tissue in obesity influences the development of colon cancer by promoting inflammation

    Journal of Physiology and Biochemistry

  7. Inflammatory markers as diagnostic and precision nutrition tools for metabolic dysfunction-associated steatotic liver disease: Results from the Fatty Liver in Obesity trial

    Clinical Nutrition, Vol. 43, Núm. 7, pp. 1770-1781

  8. Physicochemical and microbiological stability study of two new preservative-free methylprednisolone eye drops

    Farmacia Hospitalaria

  9. Rna-loaded nanoparticles for the treatment of hematological cancers

    Advanced Drug Delivery Reviews, Vol. 214

  10. Systemic messenger RNA replacement therapy is effective in a novel clinically relevant model of acute intermittent porphyria developed in non-human primates

    Gut

2023

  1. A pharmacometrics model to define docetaxel target in early breast cancer

    British Journal of Clinical Pharmacology, Vol. 89, Núm. 2, pp. 727-736

  2. Preferential expression of SCN1A in GABAergic neurons improves survival and epileptic phenotype in a mouse model of Dravet syndrome

    Journal of Molecular Medicine, Vol. 101, Núm. 12, pp. 1587-1601

2022

  1. Data on the effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with mild COVID-19.

    CORA.Repositori de Dades de Recerca

  2. Hospital Plate Waste Assessment after Modifications in Specific Dishes of Flexible and Inflexible Food Ordering Systems

    Sustainability (Switzerland), Vol. 14, Núm. 23

  3. Trastuzumab and thyroid dysfunction: An association to be aware of

    Journal of Cancer Research and Therapeutics, Vol. 18, Núm. 4, pp. 1183-1185

2021

  1. Author Correction: Epilepsy and neuropsychiatric comorbidities in mice carrying a recurrent Dravet syndrome SCN1A missense mutation (Scientific Reports, (2019), 9, 1, (14172), 10.1038/s41598-019-50627-w)

    Scientific Reports

  2. Farmacocinética y farmacogenética en la optimización de los tratamientos en psiquiatría: Revisión sistemática

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 45, Núm. 7, pp. 84-93

  3. In vivo SPECT-CT imaging and characterization of technetium-99m-labeled bevacizumab-loaded human serum albumin pegylated nanoparticles

    Journal of Drug Delivery Science and Technology, Vol. 64

  4. The importance of being able to compare: Methodologies that result in the best decisions

    Farmacia Hospitalaria

  5. Transfer of SCN1A to the brain of adolescent mouse model of Dravet syndrome improves epileptic, motor, and behavioral manifestations

    Molecular Therapy - Nucleic Acids, Vol. 25, pp. 585-602